

Dan Ziegler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1895600/publications.pdf>

Version: 2024-02-01

132
papers

14,952
citations

29994

54
h-index

18606

119
g-index

146
all docs

146
docs citations

146
times ranked

11844
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetic Neuropathies: A statement by the American Diabetes Association. <i>Diabetes Care</i> , 2005, 28, 956-962.	4.3	1,599
2	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 136-154.	4.3	1,452
3	Diabetic Cardiovascular Autonomic Neuropathy. <i>Circulation</i> , 2007, 115, 387-397.	1.6	1,062
4	Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 639-653.	1.7	675
5	Oral Treatment With $\hat{\alpha}$ -Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 trial. <i>Diabetes Care</i> , 2006, 29, 2365-2370.	4.3	491
6	Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 202-207.	1.4	462
7	Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. <i>Pain</i> , 2013, 154, 1807-1819.	2.0	428
8	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. <i>Nature Medicine</i> , 2012, 18, 926-933.	15.2	414
9	Assessment of Cardiovascular Autonomic Function: Age-related Normal Ranges and Reproducibility of Spectral Analysis, Vector Analysis, and Standard Tests of Heart Rate Variation and Blood Pressure Responses. <i>Diabetic Medicine</i> , 1992, 9, 166-175.	1.2	365
10	Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 684-694.	5.5	364
11	Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and Macroangiopathy. <i>Diabetes Care</i> , 2008, 31, 464-469.	4.3	346
12	The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With $\hat{\alpha}$ -Lipoic Acid: The SYDNEY Trial. <i>Diabetes Care</i> , 2003, 26, 770-776.	4.3	328
13	Efficacy and Safety of Antioxidant Treatment With $\hat{\alpha}$ -Lipoic Acid Over 4 Years in Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2011, 34, 2054-2060.	4.3	318
14	Early Detection of Nerve Fiber Loss by Corneal Confocal Microscopy and Skin Biopsy in Recently Diagnosed Type 2 Diabetes. <i>Diabetes</i> , 2014, 63, 2454-2463.	0.3	270
15	Diabetic cardiovascular autonomic neuropathy: Prognosis, diagnosis and treatment. <i>Diabetes/metabolism Reviews</i> , 1994, 10, 339-383.	0.2	234
16	Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. <i>Pain</i> , 2012, 153, 1148-1158.	2.0	227
17	Neuropathic Pain in Diabetes, Prediabetes and Normal Glucose Tolerance: The MONICA/KORA Augsburg Surveys S2 and S3. <i>Pain Medicine</i> , 2009, 10, 393-400.	0.9	201
18	Prediction of Mortality Using Measures of Cardiac Autonomic Dysfunction in the Diabetic and Nondiabetic Population: The MONICA/KORA Augsburg Cohort Study. <i>Diabetes Care</i> , 2008, 31, 556-561.	4.3	194

#	ARTICLE	IF	CITATIONS
19	Neuropathy in prediabetes: does the clock start ticking early?. <i>Nature Reviews Endocrinology</i> , 2011, 7, 682-690.	4.3	171
20	Epidemiology of polyneuropathy in diabetes and prediabetes. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 126, 3-22.	1.0	166
21	New perspectives on the management of diabetic peripheral neuropathic pain. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 108-119.	0.9	164
22	Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. <i>Review of Diabetic Studies</i> , 2015, 12, 48-62.	0.5	150
23	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. <i>Diabetes Care</i> , 2015, 38, 838-843.	4.3	150
24	Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy. <i>Diabetes Care</i> , 2004, 27, 2178-2183.	4.3	146
25	Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy. <i>Endocrine Reviews</i> , 2019, 40, 153-192.	8.9	140
26	Methods of investigation for cardiac autonomic dysfunction in human research studies. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 654-664.	1.7	139
27	Efficacy of $\hat{\alpha}$ -lipoic acid in diabetic neuropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2721-2731.	0.9	139
28	Novel pathogenic pathways in diabetic neuropathy. <i>Trends in Neurosciences</i> , 2013, 36, 439-449.	4.2	128
29	Painful diabetic neuropathy: treatment and future aspects. <i>Diabetes/Metabolism Research and Reviews</i> , 2008, 24, S52-S57.	1.7	126
30	Thioctic Acid for Patients with Symptomatic Diabetic Polyneuropathy. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 173-189.	1.8	115
31	Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies. <i>Clinical Therapeutics</i> , 2007, 29, 2536-2546.	1.1	115
32	Challenges in Design of Multicenter Trials: End points assessed longitudinally for change and monotonicity. <i>Diabetes Care</i> , 2007, 30, 2619-2625.	4.3	109
33	Cohort profile: the German Diabetes Study (GDS). <i>Cardiovascular Diabetology</i> , 2016, 15, 59.	2.7	97
34	Subclinical Inflammation and Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2009, 32, 680-682.	4.3	92
35	Residual microvascular risk in diabetes: unmet needs and future directions. <i>Nature Reviews Endocrinology</i> , 2010, 6, 19-25.	4.3	92
36	Older Subjects With Diabetes and Prediabetes Are Frequently Unaware of Having Distal Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2013, 36, 1141-1146.	4.3	89

#	ARTICLE	IF	CITATIONS
37	Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. <i>Diabetes Care</i> , 2017, 40, 569-576.	4.3	88
38	Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. <i>Clinical Autonomic Research</i> , 2001, 11, 369-376.	1.4	86
39	Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. <i>Diabetologia</i> , 2015, 58, 1118-1128.	2.9	85
40	Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy. <i>Diabetes Care</i> , 2010, 33, 839-841.	4.3	83
41	Statement of Retraction. <i>Diabetes Care</i> , 2008, 31, S255-S255.	4.3	82
42	Neuropathy: The Crystal Ball for Cardiovascular Disease?. <i>Diabetes Care</i> , 2010, 33, 1688-1690.	4.3	78
43	Association of Subclinical Inflammation With Polyneuropathy in the Older Population. <i>Diabetes Care</i> , 2013, 36, 3663-3670.	4.3	76
44	Prevalence of Cardiovascular Autonomic Dysfunction Assessed by Spectral Analysis and Standard Tests of Heart-Rate Variation in Newly Diagnosed IDDM Patients. <i>Diabetes Care</i> , 1992, 15, 908-911.	4.3	75
45	Painful Diabetic Neuropathy. <i>Diabetes Care</i> , 2009, 32, S414-S419.	4.3	75
46	From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 146-156.	1.2	75
47	Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. <i>European Journal of Pain</i> , 2009, 13, 582-587.	1.4	74
48	A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. <i>Pain</i> , 2015, 156, 2013-2020.	2.0	74
49	Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2009, 32, 1479-1484.	4.3	73
50	Impact of Disease Characteristics on the Efficacy of Duloxetine in Diabetic Peripheral Neuropathic Pain. <i>Diabetes Care</i> , 2007, 30, 664-669.	4.3	72
51	Whither pathogenetic treatments for diabetic polyneuropathy?. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 327-333.	1.7	68
52	Predictors of improvement and progression of diabetic polyneuropathy following treatment with α -lipoic acid for 4years in the NATHAN 1 trial. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 350-356.	1.2	66
53	Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109063.	1.1	66
54	New diagnostic tests for diabetic distal symmetric polyneuropathy. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 44-51.	1.2	64

#	ARTICLE	IF	CITATIONS
55	General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort. <i>Diabetes Care</i> , 2019, 42, 240-247.	4.3	64
56	Current concepts in the management of diabetic polyneuropathy. <i>Journal of Diabetes Investigation</i> , 2021, 12, 464-475.	1.1	56
57	Postchallenge Hyperglycemia Is Positively Associated With Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2012, 35, 1891-1893.	4.3	55
58	Prediabetic Neuropathy: Does It Exist?. <i>Current Diabetes Reports</i> , 2012, 12, 376-383.	1.7	54
59	Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. <i>Diabetologia</i> , 2017, 60, 2495-2503.	2.9	54
60	Treatment of Diabetic Polyneuropathy: Update 2006. <i>Annals of the New York Academy of Sciences</i> , 2006, 1084, 250-266.	1.8	53
61	Validation of a Novel Screening Device (NeuroQuick) for Quantitative Assessment of Small Nerve Fiber Dysfunction as an Early Feature of Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2005, 28, 1169-1174.	4.3	52
62	Corneal confocal microscopy: Recent progress in the evaluation of diabetic neuropathy. <i>Journal of Diabetes Investigation</i> , 2015, 6, 381-389.	1.1	51
63	Inflammatory markers are associated with cardiac autonomic dysfunction in recent-onset type 2 diabetes. <i>Heart</i> , 2017, 103, 63-70.	1.2	51
64	Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro. <i>NeuroMolecular Medicine</i> , 2011, 13, 266-274.	1.8	50
65	Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. <i>BMJ Open</i> , 2015, 5, e006559.	0.8	47
66	Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). <i>Diabetes Research and Clinical Practice</i> , 2018, 139, 147-154.	1.1	45
67	Current Concepts in the Management of Diabetic Polyneuropathy. <i>Current Diabetes Reviews</i> , 2011, 7, 208-220.	0.6	44
68	NADPH Oxidase Inhibition: Preclinical and Clinical Studies in Diabetic Complications. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 415-434.	2.5	41
69	Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes. <i>European Journal of Endocrinology</i> , 2016, 174, 433-443.	1.9	38
70	A gain-of-function sodium channel β 2-subunit mutation in painful diabetic neuropathy. <i>Molecular Pain</i> , 2019, 15, 174480691984980.	1.0	38
71	High prevalence of diagnosed and undiagnosed polyneuropathy in subjects with and without diabetes participating in a nationwide educational initiative (PROTECT study). <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 998-1002.	1.2	36
72	Differential Association Between Biomarkers of Subclinical Inflammation and Painful Polyneuropathy: Results From the KORA F4 Study. <i>Diabetes Care</i> , 2015, 38, 91-96.	4.3	36

#	ARTICLE	IF	CITATIONS
73	Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6Åyears in diabetic patients. <i>Acta Diabetologica</i> , 2015, 52, 65-72.	1.2	36
74	A Systemic Inflammatory Signature Reflecting Cross Talk Between Innate and Adaptive Immunity Is Associated With Incident Polyneuropathy: KORA F4/FF4 Study. <i>Diabetes</i> , 2018, 67, 2434-2442.	0.3	36
75	New vistas in the diagnosis of diabetic polyneuropathy. <i>Endocrine</i> , 2014, 47, 690-698.	1.1	35
76	Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 286-298.	3.1	35
77	The Role of Sodium Channels in Painful Diabetic and Idiopathic Neuropathy. <i>Current Diabetes Reports</i> , 2014, 14, 538.	1.7	33
78	Emerging drugs for diabetic peripheral neuropathy and neuropathic pain. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 393-407.	1.0	32
79	Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recent-onset diabetes. <i>Experimental and Molecular Medicine</i> , 2017, 49, e394-e394.	3.2	29
80	Association of Lower Cardiovagal Tone and Baroreflex Sensitivity With Higher Liver Fat Content Early in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1130-1138.	1.8	28
81	Effectiveness of Duloxetine Compared With Pregabalin and Gabapentin in Diabetic Peripheral Neuropathic Pain. <i>Clinical Journal of Pain</i> , 2014, 30, 875-885.	0.8	27
82	Treatment with α -Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-8.	1.0	27
83	Effect of Low-Energy Diets Differing in Fiber, Red Meat, and Coffee Intake on Cardiac Autonomic Function in Obese Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1750-1757.	4.3	27
84	Differential Patterns of Impaired Cardiorespiratory Fitness and Cardiac Autonomic Dysfunction in Recently Diagnosed Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 246-252.	4.3	26
85	Differential associations of lower cardiac vagal tone with insulin resistance and insulin secretion in recently diagnosed type 1 and type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2018, 79, 1-9.	1.5	25
86	Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. <i>Diabetologia</i> , 2021, 64, 2843-2855.	2.9	25
87	Clinical trials for drugs against diabetic neuropathy: Can we combine scientific needs with clinical practicalities?. <i>International Review of Neurobiology</i> , 2002, 50, 431-463.	0.9	22
88	Association of transketolase polymorphisms with measures of polyneuropathy in patients with recently diagnosed diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2811.	1.7	22
89	Cardiorespiratory Fitness and Cardiac Autonomic Function in Diabetes. <i>Current Diabetes Reports</i> , 2017, 17, 125.	1.7	21
90	Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 458-468.	2.9	20

#	ARTICLE	IF	CITATIONS
91	Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms. <i>Clinical Pharmacology: Advances and Applications</i> , 2014, 6, 195.	0.8	18
92	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Testing for Autonomic And Somatic Nerve Dysfunction. <i>Endocrine Practice</i> , 2017, 23, 1472-1478.	1.1	18
93	Myeloperoxidase, superoxide dismutase β , cardiometabolic risk factors, and distal sensorimotor polyneuropathy: The KORA F4/FF4 study. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3000.	1.7	18
94	Pronounced Reduction of Cutaneous Langerhans Cell Density in Recently Diagnosed Type 2 Diabetes. <i>Diabetes</i> , 2014, 63, 1148-1153.	0.3	17
95	Neuropathy in Diabetes: "One Cannot Begin It Too Soon". <i>Angiology</i> , 2018, 69, 752-754.	0.8	17
96	Constant hepatic ATP concentrations during prolonged fasting and absence of effects of Cerbomed Nemos [®] on parasympathetic tone and hepatic energy metabolism. <i>Molecular Metabolism</i> , 2018, 7, 71-79.	3.0	17
97	Neuropathic pain is not adequately treated in the older general population: Results from the KORA F4 survey. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 806-814.	0.9	16
98	Impairment in Baroreflex Sensitivity in Recent-Onset Type 2 Diabetes Without Progression Over 5 Years. <i>Diabetes</i> , 2020, 69, 1011-1019.	0.3	16
99	The Role of Biofactors in Diabetic Microvascular Complications. <i>Current Diabetes Reviews</i> , 2022, 18, .	0.6	16
100	Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 698-704.	1.2	15
101	Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1181-1187.	1.2	15
102	Diabetic Neuropathy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, S70-S81.	0.6	14
103	Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years. <i>Brain</i> , 2021, 144, 3251-3263.	3.7	14
104	Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes. <i>Diabetologia</i> , 2022, 65, 552-562.	2.9	14
105	Expansion and Impaired Mitochondrial Efficiency of Deep Subcutaneous Adipose Tissue in Recent-Onset Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1331-e1343.	1.8	13
106	Association of Long-Term Air Pollution with Prevalence and Incidence of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. <i>Environmental Health Perspectives</i> , 2020, 128, 127013.	2.8	13
107	Augmented Corneal Nerve Fiber Branching in Painful Compared With Painless Diabetic Neuropathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6220-6228.	1.8	12
108	Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT follow-up study). <i>Journal of Diabetes Investigation</i> , 2020, 11, 1272-1277.	1.1	12

#	ARTICLE	IF	CITATIONS
109	Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000752.	1.2	12
110	Spatial analysis improves the detection of early corneal nerve fiber loss in patients with recently diagnosed type 2 diabetes. <i>PLoS ONE</i> , 2017, 12, e0173832.	1.1	12
111	Cumulative long-term recurrence of diabetic foot ulcers in two cohorts from centres in Germany and the Czech Republic. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108621.	1.1	11
112	Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial. <i>Pain</i> , 2021, 162, 561-568.	2.0	10
113	Differential Patterns and Determinants of Cardiac Autonomic Nerve Dysfunction during Endotoxemia and Oral Fat Load in Humans. <i>PLoS ONE</i> , 2015, 10, e0124242.	1.1	10
114	Overexpression of cutaneous mitochondrial superoxide dismutase in recent-onset type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 1621-1625.	2.9	9
115	BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. <i>BMJ Open</i> , 2022, 12, e057142.	0.8	9
116	Peripheral Ion Channel Gene Screening in Painful- and Painless-Diabetic Neuropathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7190.	1.8	9
117	Early detection of neuropathy in leprosy: a comparison of five tests for field settings. <i>Infectious Diseases of Poverty</i> , 2017, 6, 115.	1.5	8
118	High-intensity interval training for 12 weeks improves cardiovascular autonomic function but not somatosensory nerve function and structure in overweight men with type 2 diabetes. <i>Diabetologia</i> , 2022, 65, 1048-1057.	2.9	8
119	German Diabetes Study "Baseline data of retinal layer thickness measured by SD-OCT" in early diabetes mellitus. <i>Acta Ophthalmologica</i> , 2019, 97, e303-e307.	0.6	7
120	Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models. <i>Molecular Metabolism</i> , 2021, 43, 101114.	3.0	7
121	Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy. <i>Current Diabetes Reviews</i> , 2022, 18, .	0.6	6
122	Management of painful diabetic neuropathy: What is new or in the pipeline for 2007?. <i>Current Diabetes Reports</i> , 2007, 7, 409-415.	1.7	5
123	Patient Expectations in the Treatment of Painful Diabetic Polyneuropathy: Results from a Non-Interventional Study. <i>Pain Medicine</i> , 2014, 15, 671-681.	0.9	5
124	Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: A double-blind, randomized, placebo-controlled, parallel group pilot study over 12 months. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107757.	1.2	5
125	Innovations in the Management of Musculoskeletal Pain With Alpha-Lipoic Acid (IMPALA Trial): Study protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Alpha-Lipoic Acid for the Treatment of Fibromyalgia Pain. <i>JMIR Research Protocols</i> , 2017, 6, e41.	0.5	5
126	Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Diabetes Care</i> 2012;35:1095-1097. <i>Diabetes Care</i> , 2012, 35, e79-e79.	4.3	4

#	ARTICLE	IF	CITATIONS
127	Associations of cells from both innate and adaptive immunity with lower nerve conduction velocity: the Maastricht Study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001698.	1.2	4
128	Comment on Haussleiter et al.: NeuroQuick “ A novel bedside test for small fiber neuropathy?. <i>European Journal of Pain</i> , 2009, 13, 217-217.	1.4	2
129	Association of persistent organic pollutants with sensorimotor neuropathy in participants with and without diabetes or prediabetes: Results from the population-based KORA FF4 study. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 235, 113752.	2.1	2
130	Effect of obesity on the associations of 25-hydroxyvitamin D with prevalent and incident distal sensorimotor polyneuropathy: population-based KORA F4/FF4 study. <i>International Journal of Obesity</i> , 2022, 46, 1366-1374.	1.6	2
131	Response to research letter in relation to paper by Bongaerts et al., A Clinical Screening Score for Diabetic Polyneuropathy: KORA F4 and AusDiab Studies (A single question screening test for the) <i>Tj ETQq1 1 0.784314 rgBT (Overloc</i>		
132	Diabetic Peripheral Neuropathy and Sexual Dysfunction. , 2007, , 277-312.		0